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Improvements in the prevention or control of re-
jection of the kidney and liver have been largely 
interchangeable (1, 2) and then applicable, with very 
little modification, to thoracic and other organs. 
However, the mechanism by which anti rejection 
treatment permits any of these grafts to be "accepted" 
has been an immunological enigma (3, 4). We have 
proposed recently that the exchange of migratory leu-
kocytes between the transplant and the recipient with 
consequent long-term cellular chimerism in both is the 
basis for acceptance of all whole-organ allografts and 
xenografts (5). Although such chimerism was demon-
strated only a few months ago, the observations have 
increased our insight into transplantation immunology 
and have encouraged the development of alternative 
therapeutic strategies (6). 
DISCOVERY OF GRAFT CHIMERISM 
After Liver Transplantation 
Successful transplants were long envisioned as an 
alien patch in a homogeneous host (Fig. 1, left). The first 
unequivocal evidence that whole-organ grafts in human 
beings become genetic composites (chimeras) was ob-
tained in 1969 with karyotyping studies in female 
recipients oflivers obtained from male cadaveric donors. 
Postoperatively, the hepatocytes and the endothelium of 
the major blood vessels of the grafts retained their donor 
sex, whereas the entire macrophage system, including 
the Kupffer cells, was replaced with recipient female cells 
(identified by their characteristic Barr bodies) within 
100 days (7, 8) (Fig. 1, middle). These observations 
attracted considerable attention at the time, primarily 
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because of their implication that liver-based inborn 
errors of metabolism could be corrected permanently by 
liver replacement (9, 10). This prediction has been met 
since then in nearly two dozen such heritable diseases 
(11). Each report of another liver-based metabolic 
disorder that was corrected by liver replacement added 
to the illusion that the composite (chimeric) structure of 
the hepatic allograft was a special feature of this organ. 
After Intestinal Transplantation 
The illusion of uniqueness of the hepatic graft was 
dispelled in 1991 with the demonstration, first in rat 
models (12) and then in human beings (13), that all 
successfully transplanted intestines also were chimeric. 
The epithelium of the bowel remained that of the donor, 
but lymphoid, dendritic and other leukocytes of recipient 
phenotype quickly became the dominant cells in the 
lamina propria, Peyer's patches and mesenteric nodes. 
The transformation in experimental animals and in 
human beings (Fig, 2) was the same whether the bowel 
was transplanted alone or as a part of a multi visceral 
graft that also contained the liver, stomach and pan-
creas. As with that of the liver graft before it, the 
chimerism of the intestinal graft was made easier to 
demonstrate by the large constituency of lymphore-
ticular cells of the normal bowel. An additional crucial 
factor was the increasing sophistication of cell pheno-
typing techniques with which to differentiate donor 
from recipient cells in either experimental animals or 
human beings. For the first time, it was speculated in 
1991 that graft chimerism might be a generic feature of 
all accepted grafts (13). This speculation soon was 
demonstrated with the kidney (14) and thoracic organs 
(15-17). 
RECOGNITION OF SYSTEMIC CHIMERISM 
Twenty-two years passed between the discovery of the 
transplanted liver's chimerism and the discovery of that 
of the intestine. Throughout this time, the tacit or 
explicit assumption was that the cells departing the liver 
had been destroyed. This misapprehension would not 
happen again with the bowel. In a letter on February 12, 
1991, accepting the article by Iwaki et al. (13) that 
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FIG. 1. Steps in understanding liver transplantation: left- historical 
view; middle - realization in 1969 that the liver graft became a genetic 
composite (chimera); right-proof in 1992 of systemic chimerism. 
Stars represent cell exchange between graft and host. 
showed the chimeric nature of the transplanted human 
intestine, Dr. Robin Fox, editor of the journal Lancet 
asked "Would you consider adding, at proof stage, a few 
words about the possible fate of the donor lympho-
cytes?" In addition to stimulating further studies of the 
intestine (see later), this inquiry caused a reexamination 
of data from much earlier investigations of kidney and 
liver transplant recipients. Circumstantial evidence 
from these cases had suggested that donor leukocytes 
migrated from the engrafted organs and were not 
promptly destroyed. However, the observations had 
been largely ignored or forgotten. 
Kidney Transplantation 
Indirect Evidence of Chimerism. Survival for at least 
5 mo after clinical kidney allotransplantation was a rare 
achievement in patients treated through April 1962. 
Only eight patients survived -two in Boston (18-20) and 
six in Paris (21, 22). The subsequent practical exploi-
tation of this operation hinged on the simple discovery 
that the rejection under azathioprine therapy of either 
canine (23) or human kidney allografts (24) could be 
reversed in the vast majority of cases with the addition 
or intensification of prednisone therapy. In addition, the 
clinical experience showed that it often became possible 
subsequently to taper the doses of both drugs (24). The 
reversibility of rejection and a change in host-graft 
relationship eventually were verified with all other 
transplanted organs, beginning with the liver (2, 25). 
The mechanism of graft acceptance under such 
therapy could not be explained (4, 26-29). An ancient 
clue was the reduced allogenicity noted in thyroid tissue 
during a period of privileged sanctuary in the anterior 
chamber of the guinea pig eye before retransplantation 
to a subcutaneous location in the same recipient (30, 31). 
Such graft "adaptation" (as Woodruff called it) in 
combination with recipient clonal lymphocyte deletion 
was used in 1963 to explain the reversal of rejection in 
the kidney recipients and the later donor-specific dimi-
nution of recipient immunological resistance to the 
transplant (24, 27) . The inability to explain how genet-
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ically proscribed transplant antigens could change 
caused the adaptation concept to lose favor. 
The results of exhaustive skin test studies (tubercu-' 
lin, histoplasmin, blastomycin, coccidioidin, mumps, 
Candida and Trichophyton) of our early Colorado 
kidney recipients and their donors provided an expla-
nation for altered graft antigenicity (32), but one that 
was not considered plausible at the time. Seventy-seven 
percent of the skin reactions that were positive preop-
eratively in the donor but not in the patients crossed 
over the previously negative recipients, along with the 
transplanted kidney (Fig. 3). When this did not occur 
(the other 23%), it meant that the kidney transplant had 
failed. W.E.C. Kirkpatrick and Charles Wilson, the 
fellows who performed these studies under the super-
vision of the immunologist, Dr. David Talmage, specu-
lated that the secondary acquisition of the positive skin 
tests was "caused by adoptive transfer of donor cellular 
immunity by leukocytes in the renal graft vasculature 
and hilar lymphoid tissue" (32). 
The implication that cells from the graft had migrated 
into recipient tissues was considered untenable nearly 
30 yr ago because the kidney was then thought to be a 
leukocyte-poor organ. Consequently, the flash of po-
tential insight faded even though the "transfer factor" 
of Lawrence (33) was suggested as a possible amplifi-
cation device. Ironically, several of these original pa-
tients were restudied and found to have chimerism 
nearly three decades later (14). By then, they had 
become part of an elite group of forerunners bearing the 
longest continuously surviving kidney grafts in the 
world (34). 
Although the empiric observations of rejection re-
versal and the seeming change in host-graft relationship 
were enigmatic in 1962 and 1963, they became the basis 
of the therapeutic dogma that has dominated the clinical 
field of whole-organ transplantation ever since. This 
dogma calls for daily baseline treatment (30 yr ago with 
azathioprine), plus intervention with the highly dose-
maneuverable adrenal cortical steroids to whatever level 
is required to maintain stable graft function. The new 
drugs that have been added through the years have been 
increasingly effective (Table 1). However, in every case 
the weaning off drugs after initially heavy induction 
therapy requires highly individualized dose adjustments 
in which each change must be evaluated after the fact by 
the patient's freedom from rejection or failure to 
maintain this state. 
Technology of Chimerism Detection. The search in 
April through July of 1992 for chimeric cells in whole-
organ recipients was made feasible by the distinctive 
features of two chromosomes. In female patients who 
had been given organs from male donors, the presence in 
recipient tissues (or blood) of cells with the Y chro-
mosome was considered unequivocal evidence of sys-
temic chimerism (14, 35). Alternatively, probes were 
used that detected human leukocyte antigen (HLA) 
alleles of chromosome 6 (5, 14, 36). For study of either 
the Y chromosome or chromosome 6, one or the other of 
two technologies, and usually both, was used (5, 14, 35, 
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FIG. 2. Repopulation of the lamina propria of human small intestinal grafts, demonstrated by HLA allele phenotyping. Monoclonal antibodies 
directed at Bw loci were used to differentiate donor (Bw6) from recipient (Bw4) cells. (A) Backtable graft biopsy specimen showed no recipient 
cells as expected. (lmmunoperoxidase staining for Bw4 [left] and Bw6 [right]; original magnification x 250.) (B) Biopsy specimen 54 days after 
transplantation . The recipient cells have repopulated the lamina propria, but the epithelium and endothelium remained of donor origin. 
Ommunoperoxidase staining with DAB [brown] for Bw4 [left] and Bw6 [right); original magnification x 250.) 
DONOR 
Positive 
Skin Tests 
n=61 
RECIPIENT 
Negative 
Skin Tests 
RECIPIENT 
Positive 
Skin Tests 
n=47 (77%) 
FIG. 3. Transfer of positive skin test results from kidney donors to 
recipients in cases at the University of Colorado from 1962 to 1964 
(32 ). Although inexplicable at the time, these observations reflected 
adoptive transfer after cell migration, repopulation and chimerism. 
36), One was cytostaining, which allows the location 
and morphological characterization of phenotypically 
distinct donor and recipient cells. The other was poly-
merase chain reaction (peR), which distinguishes donor 
from recipient DNA. 
The cytostaining for the Y probe was with a fluores-
cence method after in situ hybridization (14, 35). The 
immunostaining for the HLA markers was with indirect 
immunofluorescence, an avidin-biotin-complex immu-
noperoxidase or both methods, by use of monoclonal 
antibodies to class I and class II antigen phenotypes 
present in the donor but not the recipient (5, 14,36). The 
tissue sections were blocked with nonimmune serum 
from the source of the secondary antibody. Nonspecific 
peroxidase activity was quenched by incubation with 
H 2 0 2/methanol. Staining with irrelevant HLA anti-
TABLE 1. Treatment principles of organ transplantation 
Central therapeutic dogma 
Baseline therapy with one or two drugs 
Secondary adjustments with steroids with or without anti-
lymphoid agents 
Case to case trial (and potential error) of weaning 
Baseline Agents 
Azathioprine 
Cyclophosphamide 
Cyclosporine 
Cyclosporine and azathioprine 
FK 506 
FK 506 and azathioprine 
bodies and omission of the primary antibody provided 
negative controls. Tissues with known HLA antigens, 
along with the allograft biopsy and skin sections of the 
recipient stained with matching HLA monoclonal anti-
bodies, were used as positive-specificity controls. 
In the peR search for the Y chromosome, oligonu-
cleotides specific for the satellite region of the Y 
chromosome centromere Y-A (37) ' and for the sex-
determining region of the Y chromosome (38) were used 
as primers for determination of the presence of male 
DNA in the female recipient tissues. After Southern 
blotting, the amplified material was hybridized to 
radioactively labeled Y-specific probes for confirmation 
of the specificity of the bands visualized in an agarose gel 
after ethidium bromide staining. The peR tests for 
donor- and recipient-specific HLA alleles of chromosome 
6 were performed according to the reference protocol of 
the XI International Histocompatibility Workshop (39), 
in which preliminary generic amplification of the DRB 
gene is performed followed by allele-specific amplifi-
cation and testing. 
Direct Evidence of Chimerism. Of the five kidney 
recipients who were studied 27 to 29 yr after transplan-
tation, one had stopped immunosuppression 12 yr 
, 
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TABLE 2. Microchimerism according to lILA·allele detection with immunocytochemical (ICC) and PCR techniques 
in four kidney allograft recipients and according to sex in a fifth who could be studied with Y·chromosome detection 
(male to female donor)a 
Donor tissue distribution 
Kidney allograft Blood Lymph node Skin 
Date of transplantation Patient age at 
LDno. Donor (day/molyr)b transplantation (yr) ICC PCR PCR ICC PCR ICC PCR 
17 Mother 7/ 19/63 15 + + + + 
33 Mother 10/07/63 18 + + + + + + 
51 Aunt 2/10/64 18 + + + + + + 
52< Father 2/17/64 16 + + + + 
90 Mother 7/23/65 18 + + + + + + + 
aData from Reference 14. 
bPostoperative chimera studies performed in May and June of 1992. 
eNo treatment for 12 yr except for prednisone 7.5 mglday. Other patients still given azathioprine with or without prednisone . 
earlier, whereas the others were still taking azathioprine 
with or without prednisone. These five patients were 
selected for the chimerism study in preference to other 
surviving kidney recipients from the 1963 era for three 
reasons. First, four of the five donors still are alive, 
allowing their HLA retyping and use of their lympho-
cytes for studies of immunological competence of the 
recipient; these tests showed varying degrees of donor-
specific nonreactivity (tolerance) that in some cases was 
absolute (14). Second, known HLA incompatibilities 
between these four parental or aunt donors and their 
recipients permitted the immunocytochemical and PCR 
distinction of donor from recipient cells in the biopsy 
tissues as described in the preceding section. Finally, in 
the fifth case in which the donor (father to daughter) had 
died, chimerism in tissues could be determined by sex 
typing. 
In each of the four kidney recipients whose donor still 
was alive, leukocytes with the appearance of dendritic 
cells that had migrated from the renal allografts were 
found in the recipient skin and lymph node biopsies 
(Table 2). Although they were few in number, these 
HLA-mismatched donor cells were unmistakable with 
the immunostaining techniques (Figure 4B). Chimerism 
was confirmed with PCR in the recipient tissues of all 
four of these patients (Fig. 5) and in the blood of two of 
them (Table 2). 
In the fifth patient, a woman who had been given her 
now-deceased father's kidney 29 yr previously, cells with 
the Y chromosome were found in her skin with fluo-
rescent in situ hybridization studies, which were con-
firmed with PCR (Fig. 6). 
In all five cases, biopsy samples of the kidney showed 
that the cells departing the allograft had been replaced 
by similar cells from the recipient (Figure 4A). Thus, in 
addition to showing systemic chimerism, it was estab-
lished that the kidney grafts were chimeras-composed 
of cells with two different genomes (14) (Fig. 7). 
The Liver and Intestine 
Indirect Evidence in Liver Recipients of Systemic 
Chimerism. When hepatic graft chimerism was re-
ported in 1969 (7, 8), the fate of the donor cells vacating 
the liver was unknown. Although it was often assumed 
that these cells had perished, their continued viable 
presence in places other than the liver was signaled by 
the appearance and maintenance in the recipient blood 
flow of new donor-specific immunoglobulin types (8, 40). 
As with the circumstantial evidence of chimerism in the 
kidney recipients of 1963, this important finding was 
largely ignored. However, 15 yr later emigrant cells from 
the graft were proposed to be the source of RBC 
antibodies that developed in recipients of livers from 
donors who had ABO nonidentity (41). Subsequently, 
Davies, Pollard and Calne (42) showed the appearance in 
liver recipients of new circulating donor-specific class I 
antigens, which they attributed to the graft hepatocytes. 
However, because these molecules are known to come 
from bone marrow-derived macrophages, dendritic cells 
or both (43-45), they presumably had the same donor 
origin as the additional immunoglobulin types and red 
cell antibodies after completion of cell migration to 
extrahepatic sites. 
Direct Evidence of Systemic Chimerism from the 
Intestine. The evidence of systemic chimerism after 
either liver or intestinal transplantation remained cir-
cumstantial until Murase et al. (46, 47) showed with 
flow cytometry that the stromal leukocytes leaving the 
small bowel allografts in rat recipients treated with a 
short course of FK 506 homed through vascular routes 
to widely distributed host lymphoid tissues. This 
created a state of systemic mixed allogeneic chimerism 
for at least 45 days (Fig. 8), free of lethal or even 
detectable graft vs. host disease (GVHD) except in 
special strain combinations in which a poorly under-
stood imbalance exists between the graft and recipient 
immune systems. 
The vascular route by which cell migration occurred 
also was obvious in swine (48) and in human recipients 
of intestinal or liver-intestinal grafts (13, 49). In the 
patients, donor cells in the early postoperative period 
accounted transiently for 5% to 15% of circulating 
mononuclear cells, usually without evidence of GVHD. 
Because the circulating cells could no longer be detected 
with flow cytometry after 1 to 2 mo in the clinical cases 
(Fig. 9) and were not studied beyond this time in the rat 
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FIG. 4. Patient LD5l. Immunostained biopsy samples 29 yr after 
transplantation of (A) an allograft kidney (original magnification 
x 250) and (B) an inguinal lymph node (original magnification x 100) 
stained for HLA B7,40-an antigen present in the donor but not the 
recipient; note the sparse and evenly scattered donor cells (rust 
colored) in the lymph node. (C) As a control the lymph node was also 
stained with anti-A2,28-present in neither the donor nor the 
recipient (original magnification x 100). 
experiments, the duration of the chimeric state re-
mained in doubt throughout 1991. 
Metabolic Effects of Migratory Cells from Liver Al-
lografts. Meanwhile, an incidental and at first inexpli-
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FIG. 5. Chimerism demonstrated by HLA molecular typing in a 
kidney recipient, LD5l. The donor's DR2 allele was specifically 
amplified by PCR from DNA extracted from the recipient's blood (RB), 
lymph node (RL) and skin (RS). The amplified product was dot blotted 
and hybridized with 7011, a DR2-specific oligonucleotide probe. DNA 
from the donor's blood (DB) was also amplified. The negative control 
(C) of the PCR amplification performed in the absence of DNA is also 
shown. 
2 3 4 5 6 7 8 9 
FIG. 6. PCR demonstration of chimerism in a female recipient 
(LD52) of a kidney from her father. The DNA of the SRY region of the 
Y chromosome was PCR amplified, Southern blotted and hybridized 
with a homologous radioactive probe. DNA from biopsy specimens of 
the patient's kidney (1), blood (3), lymph node (4) and skin (5) were 
tested. As controls, DNA from an unrelated female (6) and serial 
dilutions of male DNA in female DNA 10- 4 (9), 10- 5 (8) and 10- 6 (7) 
were also analyzed. No sample was present in lane 2. 
cable observation had been made in children treated 
with liver transplantation for the liver failure associated 
with type IV glycogen storage disease (GSD IV)-
pointing not only to the ubiquitous distribution of the 
migratory donor cells but also to their persistence and 
their metabolic influence. In GSD IV, a deficiency of the 
branching enzyme alpha-1,4-glucan:alpha-1,4-glucan 
6-glycosyltransferase (50) is responsible for the wide-
spread accumulation intracellularly and extracellularly 
of an insoluble and irritating amylopectin-like polysac-
charide (50, 51). 
The usual clinical consequence is fatal cirrhosis within 
1 or 2 yr after birth_ However, patients who do not die 
from liver disease are subject to lethal cardiomyopathy 
or neuromuscular syndromes (52-55). Because the 
enzyme deficiency and consequent amylopectin depo-
sition affect all cells, not just those in the liver, it was 
surprising to many experts in metabolism when ab-
sorption occurred of the amylopectin from the heart and 
other extrahepatic tissues of five patients with GSD IV 
1.3 to 6 yr after liver replacement (Fig_ 10) (56). This 
finding caused Howell (57) to predict in an accompa-
nying editorial that an explanation for the benefit "will 
teach us a great deal about transplantation." The 
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FIG. 7. Systemic and graft chimerism in all five tested patients 
treated who had borne continuously functioning allografts for 27 to 29 
yr. The stars represent the migrated cells. In these studies only the 
kidney, skin, lymph nodes and blood were sampled, but the more 
Ubiquitous chimerism was inferred from the more extensive studies in 
recipients of livers and other organs. 
prophecy was fulfilled with the further study of two of 
these recipients after 22 more mo of follow-up, showing 
that they had systemic chimeras (5, 36). 
The donor cells in these two patients had migrated 
diffusely from the transplanted liver into the heart and 
other tissues where they were evident 37 and 91 mo 
postoperatively (Table 3). There, the relocated leuko-
cytes apparently served as enzyme carriers. Similar 
chimerism in a variety of host tissues including the bone 
marrow (Table 3) with consequential metabolic benefits 
(Fig. 11) also were observed 26 mo after liver transplan-
tation in a patient whose diagnosis was type 1 Gaucher's 
disease (36), a disorder caused by a deficiency of the 
lysosomal enzyme B glucocerebrosidase (58) . The chi-
merism was demonstrated with the immunostaining 
techniques that identify individual cells with donor-
specific monoclonal HLA antibodies (Fig. 12). 
In confirmatory studies donor DNA was found with 
peR in the same locations as with immunostaining (Fig. 
13). Even with the limited samples available from these 
patients, it was evident by this time (Table 3) that the 
cell migration after clinical (5, 36) or experimental liver 
transplantation (16) was a miniversion of bone marrow 
transplantation (59) (Fig. 1, right). 
These findings explained why patients with lysosomal 
storage disorders previously thought to be correctable 
only with bone marrow transplantation (60) had bene-
fited from liver replacement beyond what had been 
predicted. These disorders included the following: Gau-
, 
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cher's disease (61), Wolman disease (62), Niemann-Pick 
disease (63) , and sea-blue histiocyte syndrome (64; 
Starzl et al., Unpublished follow-up). In such patients' 
and those with GSD IV, the enzyme produced by the 
donor cells was postulated to have obtained efficient 
access to the storage substrate by a coculture effect on 
the contiguous recipient cells, as has been described in in 
vitro experiments by Neufeld (65) . The number of the 
allogeneic cells required to achieve such a metabolic 
effect in vivo appeared from our clinical observations to 
be surprisingly low. The presumed transmission of 
enzymes from a small to a large cell population raised 
important questions about the potential cell-to-cell 
effect of other molecules directly involved in immuno-
logical processes including tolerance induction. 
Moreover, in a strictly metabolic context, it was 
evident that the past use of liver transplantation to 
investigate certain inborn metabolic errors could have 
led to erroneous conclusions if it was assumed (as it 
commonly was) that the leukocytes replaced from the 
hepatic allograft were eliminated. For example, the 
decline in cholesterol levels after liver transplantation in 
patients with familial hypercholesterolemia (66) was 
ascribed to the new supply of low-density lipoprotein 
receptors of the allograft hepatocytes (67) . It seems 
likely now that the amelioration of this disorder by liver 
transplantation is explained in part by low-density 
lipoprotein receptors of widely disseminated donor cells 
that are not hepatocytes. The volume of these leukocytes 
is large. Migratory Kupffer cells alone constitute 10% to 
15% of all cells in the liver and account for one fifth of 
the total hepatic lysosomal volume (68). 
If, as we eventually concluded (5, 6, 14, 35, 36), 
chimerism, differing only in degree in different kinds of 
organs, is an integral feature of all successful engraft-
ments, any transplantation procedure could result in a 
gain of metabolic function as suggested for different 
reasons by Groth et al . (69) two decades ago. The 
chimerism in our long-surviving kidney recipients was 
only one fifth or less of that in the liver recipients. 
However, there may have been enough cells migrating to 
the native kidneys from successfully implanted renal 
allografts (see Fig. 7) to explain recovery of function in 
the diseased kidneys, which had been shut down by the 
glycosphingolipid accumulations of Fabry's storage 
disease (70) . 
The Incidence and Duration of Chimerism in Liver 
Recipients. The concept that long-lasting graft and 
systemic chimerism is a necessary condition of graft 
acceptance was largely speculative well into 1992. The 
biopsy studies of the children with GSD IV and Gau-
cher's disease were not performed until April of that 
year, and although these gave decisive results, there 
were only three cases. However, in addition to these 
patients and those with long-surviving kidney allografts, 
another study was under way ofliver recipients who had 
survived for at least 10 yr. These patients remained from 
a starting group of 210 treated at the University of 
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FIG. B. Current understanding of the graft and systemic chimerism that occurs after intestinal transplantation. The automatic production 
of mixed allogenic chimerism after intestinal transplantation, providing the preexisting immunological apparatus, is not iatrogenically damaged 
on either donor or recipient side (see text). Evolution of this concept permitted successful clinical intestinal transplantation trials (lOB). The 
stars represent the cell exchange between the graft and host. 
Colorado between 1963 and 1980 (n = 184) and at the 
University of Pittsburgh during 1981 (n = 26) (Fig. 14). 
They were pioneer patients in the development of liver 
transplant technology (71, 72) and included the 10 
longest-surviving liver recipients in the world (73). 
From the original 210, there were 50 survivors (24%) 
at the end of the first decade. Of these, six died from 
causes shown in Table 4 beyond 10 yr but before the 
commencement of the study; a seventh mortality after 
18.4 yr occurred in July 1992 as the result of viral CAR. 
Three of these seven late losses were of patients who had 
normal liver function; the deaths were caused by 
recurrent malignancy, AIDS (from a blood transfusion 
during an orthopedic operation) and a smoke inhalation 
accident during demonstration of fire-fighting equip-
ment. Although the grafts had deteriorated in the other 
four cases, rejection had not been the cause of failure . 
The clinical profile of all 44 patients still surviving in 
January 1992, including the 1 who died during the study 
period, is shown in Table 5. All but two ofthe recipients 
were in good clinical condition, and only three had 
significantly perturbed liver function test results; the 
highest bilirubin level was 3.8 mg/dl. Immunosup-
pression was variable. Most of the patients treated 
before 1980 were given azathioprine, whereas those 
treated during the 1980 to 1981 period were usually still 
given their starting drug of cyclosporine or had been 
switched to FK 506. The majority of patients in both the 
pre-1980 and post-1980 eras were still receiving main-
tenance prednisone (Table 6). A particularly important 
group of six patients had stopped their baseline immu-
nosuppression 1 to 11 yr after transplantation and had 
been free of these drugs for 5 to 13 yr (Table 7). Five of 
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FIG. 9. Appearance of donor mononuclear cells in the blood of an 
intestinal human transplant recipient (upper) and the demonstration 
of progressive replacement of interstitial donor leukocytes from the 
graft during the same general time (lower) . (Data from Iwaki et al . 
[13].) 
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FIG. 10. (A) An endomyocardial biopsy specimen obtained in 1989, at the time ofliver transplantation, revealed diffuse amylopectin deposits 
within and between cells. (B) A repeat endomyocardial biopsy sample taken in 1992 revealed only traces of extracellular deposits . (Periodic 
acid-Schiff-D; original magnification x 100.) 
FIG. 11 . (A) Hepatic hilar lymph node removed in April 1990 at the time of liver replacement from a patient with Gaucher's disease and (8) 
an inguinal lymph node obtained in June 1992. Note the marked decrease in the number of Gaucher's cells, which were difficult to find in the 
latter specimen. (Periodic acid-SchifT; original magnification x 250.) 
Case 
1 
2 
3 
TABLE 3. Metabolic diseases" 
Disease 
GSD IV 
GSD IV 
Gaucher's 
Chimerism 
Blood, skin , lymph node and heart 
Blood, skin, lymph node and heart 
Blood, skin, lymph node, intestine and 
bone marrow 
aOriginal data from references 5 and 36. 
these six also had stopped prednisone treatment at the 
same time; the sixth recipient still took 10 mg/day, 
After these preliminary inquiries were completed, 20 
randomly selected patients were invited to corne to 
Pittsburgh in May and June for biopsy studies of the 
liver, skin and lymph nodes. Of the 20, 15 remained on 
immunosuppression, whereas the other 5 had stopped 
all treatment 7 to 13 yr earlier. More extensive tissue 
collections were obtained (Tables 8 and 9) from two 
additional recipients. One was the male recipient (OT 
77) who had died after 18.4 yr of complications of CAR 
caused by HBV that had been acquired after transplan-
tation; the tissue sampling was at autopsy. The other 
patient was a woman (OT 182) in whom retransplan-
tation was performed successfully on April 2, 1992 
(Table 8). Her primary transplantation had been in 
August 1980, and although she had stopped taking 
cyclosporine in 1985 while continuing to take pred-
nisone 10 mg/day, the excised allograft and several 
previous biopsy specimens contained evidence of re-
current chronic C virus hepatitis (HCV) but not of 
rejection. Multiple host tissues were taken at the 
reoperation, including portions of jejunum from the 
Roux-en-Y biliary reconstruction and an ellipse of her 
aorta removed for a Carrel patch arterial reconstruction. 
Nine of the 22 studied were female patients who had 
been given livers from male donors (Table 8). In all nine 
the Y chromosome was demonstrated in the skin or 
lymph nodes with fluorescence in situ hybridization 
(Fig. 15) and confirmed in every case by PCR (Fig. 16), 
In seven of the nine cases, HLA phenotyping or 
HLA-DRB molecular typing also was performed on the 
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FIG. 12. Allograft liver and inguinal lymph node biopsy specimens obtained 26 mo after the liver replacement from the recipient with Gaucher's 
disease. These were stained with antibodies to DR1 (donor) and DR3 (control). (A) Note the presence of DR I-positive donor cells (green) in the 
portal tract of the liver (original magnification x 400). (B) Absence of staining in the control (antibodies to DR3; original magnification x 400). 
(C) Rare DR1-positive (donor) cells were also seen in the inguinal lymph node (original magnification x 250). (D) The lymph node control 
(antibodies to DR3) was negative (original magnification x 250) . (All were stained with FITC indirect immunofluorescence.) 
Control 
Small Bowel 
Skin 
Bone Marrow 
Blood 
I Liver 
FIG. 13. Detection of chimerism by molecular HLA class II typing in 
various tissues after liver transplantation in a patient with type 1 
Gaucher's disease. Southern blot analysis of DR1-specific amplifi-
cation of the DNA extracted from small bowel, skin, bone marrow, 
blood and liver. The denaturated DNA present on the nylon membrane 
was hybridized to a radioactively labeled DRI (donor) specific oligo-
nucleotide probe (7001). In the case of the liver, only 1/100 of the 
amplification product was used. Note negative control of the PCR 
amplification. 
Orthotopic Liver Transplantation 03/01/63 - 12/10/81 
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FIG. 14. Life survival curve of the first 210 patients in our 
Colorado-Pittsburgh series. The survival is actual to 11 yr and 
actuarial thereafter. Fifty of the original 210 patients survived for 
more than 10 yr; 43 are still alive after 11 to 23 yr . The other 7 died 
after 11.1 to 18.4 yr. 
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TABLE 4. Liver transplantation: causes of death beyond 10 yr 
Age at Date of 
OT transplantation transplantation Date of death Survival Liver 
no. (yr) Original diagnosis (mo/day/year) (mo/day/year) (yr) function Cause of death 
53 1.7 A·1·A 2/20/72 6/13/85 13.3 Ahnormal B·cell lymphoma 
(jaundiced) 
56° 18 Congenital hepatic 5/15/72 12/29/84 12.6 Abnormal GI hemorrhage 
fibrosis 2/2/84 (not jaundiced) 
77b 16 Viral CAH (non-A, non-B) 2/3/74 7/14/92 18.4 Abnormal GI hemorrhage 
(jaundiced) 
114 27 Epithelioid hemangioen- 9/19/76 11/19/91 15.2 Normal Recurrent tumor 
dothelioma 
135 34 Alcoholic cirrhosis 8/13/77 9/14/88 ILl Abnormal Recurrent alcoholic 
(jaundiced) cirrhosis 
139 23 Viral CAH (non-A, non-B) 11/13/77 5/2/89 11.6 Normal AIDS 
155 11 A-1-A 10/6/78 6/9/91 12.7 Normal Inhalation accident 
°The portal vein was thrombosed and unreconstructable at the time of retransplantation in February 1984. 
bDied during period of 1992 study. 
A-1-A = Ci,-Antitrypsin deficiency. 
TABLE 5. Profile of 44 liver transplant survivors after 
10 to 22 yr" 
Parameters 
Original diagnosesb 
Biliary atresia 
CAH 
Ci,-Antitrypsin 
PBC 
Wilson's disease 
Secondary biliary cirrhosis 
Alcoholic cirrhosis 
Budd-Chiari syndrome 
Hepatoma 
Familial cholestasis 
Neonatal hepatitis 
Age at operation (yr)C 
Length of follow-up (mo)C 
Liver function 
Bilirubin (mg/dl)< 
Albumin (gm/dl)< 
AST (IUILY 
apatients alive as of January 1992. 
bData expressed as no. of patients. 
CData expressed as mean ± S.D. 
Data 
11 
10 
6 
4 
3 
3 
2 
2 
20.2 :t 15.3 
174.3 :t 40.2 
0.8 ± 0.7 
4.0 :t 0.6 
40.2 :t 28.9 
same tissues with demonstration of chimerism in each 
case (Table 8). 
Similarly, chimerism was diagnosed in the other 13 
patients who were studied with only HLA detection 
techniques (Table 9). The availability of appropriate 
monoclonal antibodies made HLA phenotyping feasible 
in eight of these cases (Fig. 17); all eight were positive. 
The HLA molecular (PCR) typing showed the chimerism 
in all 13 cases (Fig. 18 and Table 9). 
Thus, all of the 22 patients had systemic tissue 
chimerism, which was demonstrated by one to as many 
as four techniques. In addition, the 65% incidence of 
blood chimerism with either the PCR Y probes (6 of 8; 
Table 8) or the HLA molecular probes (7 of 12; Table 9) 
TABLE 6. Immunosuppression in 44 survivors 
Amount 
No. of administered 
Group patients Drugs (mg/day) 
12 Azathioprine 50 ± 26° 
Prednisone 8.7 :!: 3.20 
2 11 Cyclosporine 266 :t 1320 
Prednisone 6.6 ± 3.4" 
3 5 Cyclosporine 232 ± 132° 
4 3 Azathioprine 58 ± 14° 
Cyclosporine 158 :!: 38° 
Prednisone 9.2 ± 1.4° 
5 2 Azathioprine 75, 50 
6 3 Azathioprine/cyclo- 25, 50/250, 100 
sporine 
7 FK 506/prednisone 6/15 
8 FK 506 10 
9 1 Prednisone 10 
10 5 Nothing 
°Data expressed as mean ± S.D. 
was noteworthy. The ubiquitous nature of the chi-
merism was especially well demonstrated with the 
extensive tissue collections in the two patients in whose 
grafts recurrent viral hepatitis developed, leading to 
retransplantation (Table 8 and Fig. 16) or to autopsy 
(Table 9 and Fig. 18). 
In addition to the invariable presence of systemic 
chimerism in these 22 patients, the studies emphasized 
the stability of the chimerism. Prolonged discontinuance 
of maintenance immunosuppression by 6 (13.6%) of the 
44 patients (Tables 6, 7 and 9) had occurred. Peripheral 
blood lymphocytes from four of the drug-free patients 
and from 7 of those still on immunosuppression had 
normal in vitro proliferative responses to concanavalin A 
and phytohemagglutinin and to third-party mixed lym-
phocyte culture (MLR). Although donor cells were not 
available for MLR testing, many or most of these long 
survivors were thought to have stable donor-specific 
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TABLE 7. Features of six liver recipients who had stopped immunosuppression 
Prednisone 
OTno. Year of transplant Year drug stopped Years drug free (mg/day) Liver function 
73 1973 1982 10 Normal 
92 1974 1985 7 Normal 
125 1977 1987 5 Normal 
150 1978 1979 13 Normal 
169 1979 1981 11 Normal 
182 1980 1985 7 10 Failing" 
aRecurrent CAH from HCV was the biopsy-proved diagnosis, confirmed in the graft hepatectomy specimen obtained at retransplantation. 
TABLE 8. Microchimerism according to V-chromosome detection with in situ hybridization or peR 
Tissue distribution 
Age of Liver allograft Blood Lymph node Skin 
Date of patient at 
OT transplantation transplantation In situ In situ In situ 
no." (mo/day/yr)Q (yr) hybridization peR peR hybridization peR hybridization peR 
64 2/18/73 3 +++ +++ + + + 
105 1/21/76 30 +++ +++ + + + + 
140 1/04/78 2 +++ +++ + + + + NT 
142 2/26/78 5 +++ +++ + + + + NT 
166 9/09/79 35 +++ +++ + + + + + 
ill 3/09/80 29 NT +++ NT NT + 
173 3/21/80 34 +++ +++ + + + 
182b 8/29/80 28 +++ +++ NT + + 
223 12/28/81 45 +++ +++ + + + + + 
In addition to Y-chromosome detection, patients underlined also were shown to have chimerism in the same tissues by immunocytochemical 
detection of donor HLA alleles (cases 142, 171 and 223) or by PCR molecular typing (all but 171 and 182). 
NT = not tested. 
aAll postoperative studies completed in April to June 1992. 
bThis patient also tested positive for Y chromosome in the intestine with in situ hybridization and in multiple tissues including the aortic 
wall with PCR (see Fig. 16). 
nonreactivity (tolerance) that was no longer drug de-
pendent. For most of the 37 other long survivors still 
receiving immunosuppressive therapy, drug weaning 
has been started. 
Thoracic Organs 
In human beings (15) and rats under immunosup-
pression (16, 17), the thoracic viscera participate in the 
same cell migration process (Fig. 19). Figure 20 shows a 
biopsy specimen obtained on September 28, 1992, of the 
sigmoid colon of a female patient who had received both 
lungs from a male donor 3 mo previously. The male cells 
in the colon reflected the evolution of chimerism rather 
than being diagnostic of GVHD. 
Even though the responsible cell migration is common 
to all organs, quantitative differences have been found 
between the heart and lung. In untreated rats Prop and 
coworkers (74, 75) have shown that the leukocyte-poor 
heart is less vigorously rejected than the lung that 
contains rich bronchus-associated lymphoid tissue. 
However, this order of susceptibility to rejection was 
reversed with one or two postoperative doses of cyclo-
sporine that often induced permanent acceptance of the 
lung but never of the heart. The authors explained the 
paradox by the greater volume of the lung's lymphoid 
and dendritic cell migration in much the same context as 
our hypothesis of graft acceptance (5). Permanent graft 
acceptance after a brief induction course of FK 506 also 
has been shown in rats to be more difficult to achieve 
with the leukocyte-poor heart than with the liver (3, 4), 
a difference that was reflected in the disappearance 
histopathologically of the seeded peripheral donor cells 
after heart but not liver engraftment (16). 
CELL TRAFFIC AND IMMUNOSUPPRESSION 
Thus, cell migration is a striking phenomenon after 
the transplantation of all whole organs, as was first 
shown in detail by Hayry's research on the kinetics of 
rejecting experimental kidney allografts (76). However, 
whether this leads to rejection or graft acceptance 
depends on the quality of immunosuppression, the 
quantity and kind of immunocytes in the organs, 
donor-recipient histocompatibility and perhaps multiple 
other factors. The donor cells departing the solid-organ 
graft and the recipient cells entering it include the 
passenger leukocytes that were suggested by Snell (77) 
and proved with in vivo experiments by Steinmuller (78) 
to be the principal cause of allograft immunogenicity. 
Steinman and Cohn (79-82) delineated the most im-
portant of these cells as a distinct family of bone 
marrow-derived antigen presenting dendritic leuko-
cytes that are distributed throughout the body including 
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TABLE 9. Microchimerism in 13 patients according to HLA-allele detection with immunocytochemical 
(ICC) phenotyping and PCR" 
Tissue distribution 
Age of 
Date of patient at Liver allograft Blood Lymph node Skin 
transplantation transplantation 
OTno. (mo!day!yr)" (yr) ICC PCR PCR ICC PCR ICC PCR 
Receiving treatment 
42 3/23/71 16 NT + + NT + NT + 
46 7/31/71 3 +++ + + + + + + 
77c 2/03/74 16 NT + NT NT + NT NT 
133 7/26/77 44 NT + NT + + 
144 4/17/78 39 +++ + + + + + 
146 6/14/78 49 NT + + NT + NT 
175 4/13/80 41 NT + + NT + NT + 
189 5/09/81 2 +++ + + + + + + 
194 7/12/81 26 +++ + + + + 
Not receiving treatment 
73 10/08/73 4 +++ + + + + 
92 11/27/74 11 +++ + + + + 
150 7/15/78 15 NT + + + + 
169 12/03/79 21 +++ + + + + + 
NT = not tested . 
"These patients were in addition to the nine studied with Y-chromosome detection (Table 8). 
bAll postoperative studies in April to July 1992. 
cSkin and blood not taken at autopsy. However, all other tissues tested positive with peR for donor DNA (see Fig. 18). 
the interstitium of the kidney, heart and other organs 
once thought to be nearly devoid of immunologically 
active cells (79, 83, 84). 
The evidence implicating these antigen-presenting 
cells in the elicitation of primary T-cell alloimmunity 
(85-87) has prompted efforts to eliminate them before 
transplantation by a variety of means (88-91). It remains 
to be determined if the reduction in this way of natural 
graft antigenicity is beneficial and, if so, under what 
circumstances. The fine margin between rejection and 
graft acceptance was illustrated by Armstronget al. (92), 
who found an association between the increased rate of 
dendritic cell replacement and the survival of kidney 
allografts transplanted to rats after they had been 
lightly immunized by blood transfusion from the donor 
strain. 
Contrary to the dendritic cell-depletion approach, an 
alternative may be to promote, not impede, two-way cell 
migration while using powerful medications or other 
means to avoid the graft destruction, GVHD or both that 
are the normal and inevitable consequences of the 
migration without such therapeutic intervention. 
Viewed in this way, it does not appear to matter in 
principle how the immune reaction is disrupted, but only 
that this disruption be achieved efficiently without 
eliminating all of the migratory cells. 
The emasculated but living cells that normally cause 
graft immunogenicity and rejection become instead the 
missionaries subserving chimerism, graft acceptance 
and, ultimately, tolerance. The antilymphoid agents (93, 
94) and a variety of monoclonal antibodies have been 
particularly effective for tolerance induction in large 
outbred experimental animals. Figure 21 shows the 
steps at which some of the old and new drugs disrupt the 
function of the lymphocyte. This disruption can occur at 
the level of antigen processing (for example deoxysper-
gualin); at an early stage in T-cell activation, as occurs 
with cyclosporine and FK 506; or distal to this with 
rapamycin, which does not inhibit the secretion of cyto-
kines including interleukin-2 but blocks their action. 
The so-called antiproliferative drugs (of which azathio-
prine was the prototype) work even more distally. 
BACK TO THE FUTURE 
The thesis that the chimerism after cell migration and 
repopulation is the generic explanation of graft accep-
tance augments the foundation of transplantation im-
munology that came from Medawar and his two prin-
cipal associates, Billingham and Brent. If rejection was 
an immunological response as Medawar declared 50 yr 
ago (95), a logical strategy to prevent it would be to treat 
the recipient with agents that were known from other 
evidence to reduce immune reactivity. By 1951 Medawar 
(with Billingham and Krohn) (96) and the American 
Morgan (97) had taken this crucial step by showing that 
skin graft survival was prolonged with cortisone acetate 
and corticotropin. The year before, Dempster of Ham-
mersmith Hospital, London, had demonstrated miti-
gation of skin graft rejection with total body irradiation 
(98). 
The Handmaidens of Tolerance and GVHD: The In 
Vivo One-way MLR 
Seemingly, these were small steps because the pro-
longation of allograft survival was limited to a few days. 
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FIG. 15. Studies of patient OT64, 19.5 yrs after her liver re-
placement from a male donor. Fluorescent in situ hybridization with 
the DYZ1 probe for the Y chromosome was used to differentiate male 
from female cells. (A) The allograft liver was used as a positive control. 
About 60% of hepatocytes and a few sinusoidal cells retained the donor 
genotype; the Y chromosome in the negative hepatocytes was likely 
excluded from the 2 f.Lm-thick sectioning plane. The yellow cyto-
plasmic material is autofluorescence (original magnification x 250). 
(B) Oil immersion microscopy was used to illustrate the variety of 
signals obtained in the liver, which showed a beaded to reticular 
pattern, often located at the periphery of the nucleus (original 
magnification x 1,000). (e) Skin biopsy specimen: spindle-shaped 
stromal cells, with a similar signal for the Y chromosome, were 
sparsely distributed (original magnification x 1,000). 
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FIG. 16. Detection of chimerism by peR in a female recipient 12 yr 
after transplantation of a liver from a male donor. The samples were 
obtained at the time of successful retransplantation, necessitated by 
HeV infection of the primary graft. The DNA of the SRY region of the 
Y chromosome was peR amplified, Southern blotted and hybridized 
with a homologous radioactive probe. Liver (L), lymph node (LN), skin 
(S), aorta (A) and intestine (/) of the patient were tested. DNA from an 
unrelated female ('i') and male DNA diluted 1: 100,000 in the female 
DNA (10 -6) were also amplified as negative and positive controls. 
However, Billingham, Brent and Medawar (99) raised 
expectations to a new level by showing that permanent 
immunological tolerance to skin grafts could be acquired 
by inoculation of immunocompetent adult spleen cells 
into fetal and perinatal mice. Main and Prehn (100) were 
able to mimic these conditions of ontogeny in adult mice 
using supralethal total body irradiation followed by bone 
marrow alloreconstitution. When the reconstituted chi-
meric mice were shown in later life to be permanently 
tolerant to donor-strain skin, the clinical possibility of 
creating radiation bone marrow chimeras as a means to 
the end of solid-organ transplantation seemed obvious. 
These hopes were soon dashed when the concept was 
delineated by Billingham and Brent (101) that an 
immune-competent graft could destroy the host. This 
was termed GVHD or "runt disease." 
What was lost track of later was that these whole-
animal models and the subsequently exploited F 1 hybrid 
models were almost artifacts in the context of clinical 
whole-organ transplantation in that the interactions of 
the two-way cell migration and repopulation shown in 
Figure 22 were precluded: by the immature state of one 
party (the Billingham-Brent-Medawar model), by the 
cytoablation used by Main and Prehn (and later bone 
marrow transplanters) or by genetic manipulation (the 
parent F 1 hybrid offspring model) (Fig. 23). 
These were whole-animal analogs of the one-way MLR 
in vitro techniques that were developed much later 
by Bain, Vas and Lowenstein (102) and Bach and 
Hirschhorn (103) (Fig. 24). The precision of the one-way 
in vitro systems allowed easy interpretation of results 
that usually showed a good correlation between histo-
compatibility and the immune reaction of the target 
lymphocytes to killed or inactivated donor lymphocytes. 
Because the natural phenomena of cell migration and 
repopulation are now known, it may be asked if the 
relevant in vitro (or surrogate) model of clinical trans-
plantation for at least some purposes should be the 
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FIG. 17. Studies of patient OT46, 21 yr after liver transplantation. 
An HLA-Al (donor) antibody was used to detect donor cells in the 
allograft liver and in an excised inguinal lymph node. Immunofluo-
rescence staining was used. (A) Note the staining of bile duct and 
endothelial cells of a mildly inflamed portal tract, whereas the 
inflammation is not stained. Faint sinusoidal Al positivity can also be 
seen (antibodies to AI; original magnification x 400) . (B) Rare 
AI-positive cells were also seen in the inguinal lymph node (antibodies 
to AI; original magnification x 400) . (e) Substitution of mouse IgM for 
the primary antibody in the same node was negative (mouse IgM; 
original magnification x 400) . 
two-way MLR in which the effect of two cell popula-
tions - each on the other - can be studied (Fig_ 22). 
However, this is hindsight many years later. Between 
1959 and 1963 and without the benefit of this infor-
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mation, the intellectual root that had grown from 
Medawar's seed bifurcated and reached the surface 
looking like two separate trees (Fig. 25)_ The differences· 
between what actually were branches of a common root 
reflected divergent therapeutic dogmas. The bone 
marrow branch with its precondition of cytoablation 
(Fig. 25, right) mimicked the Billingham-Brent-
Medawar model and was the in vivo version of a one-way 
MLR HLA matching was crucial. Engraftment in a 
drug-free state (called tolerance) was a realizable ob-
jective with perfect matching. This goal was achieved 
clinically in 1968 when Good's team successfully treated 
a patient with severe combined immune deficiency 
disease (104), followed in a few months with successes by 
Thomas (105), Good and others for hematological 
disorders not characterized by immune deficiency. 
However, even with major histocompatibility complex 
compatibility, GVHD was a constant threat. 
The reason for the virulence of the GVHD with an 
HLA mismatch was the complete or nearly complete 
removal in the cytoablated recipients of a counterweight 
to the transplanted immunocytes (Fig. 26). Immune 
modulation usually could control non-major histocom-
patibility complex reactions responsible for GVHD, 
rejection or both, and it could keep an acceptable 
donor-recipient immunological balance if perfect match-
ingoccurred. With significantly mismatched donors, this 
was not possible or required dangerous levels of immu-
nosuppression. 
Although the concept of GVHD was developed with 
bone marrow and splenocyte transplantation, it was 
recognized early (106) that the same problem was apt to 
bedevil attempts to engraft lymphoid-rich whole organs 
such as the intestine (Fig. 23). This theory was proved 
by Monchik and Russell (107) in their classical intestinal 
transplant experiments using parent rat donors whose 
bowel the F 1 hybrid recipients cannot recognize as alien 
while being subject to attack by its immunological 
component. The fear of GVHD generated by these 
results and the use of inappropriate means to prevent it 
discouraged efforts to transplant the human intestine 
for many years. 
Mixed Chimerism and Wlwle Organs: The In Vivo 
Two-wayMLR 
By the early 1960s whole-organ transplant physicians 
and surgeons, who had broken ranks with their bone 
marrow colleagues (Fig. 25, left), empirically developed 
long-term immunosuppression, with which success 
(called graft acceptance, not tolerance) did not de-
pend on matching and could be accomplished without 
GVHD - eventually extending even to the trans-
plantation of lymphoid-rich organs such as the intestine 
(12, 13,49, 108-110). The GVHD resistance now can be 
explained by the mutual engagement and interaction of 
migratory cells from the allograft with the immunocytes 
of the recipient (a two-way MLR) (Fig. 22) with the long 
survival of both (mixed chimerism) . For intestinal 
transplantation, it finally was realized that the best 
strategy was not to iatrogenically unbalance the preex-
isting immunological apparatus of either the recipient or 
the graft (108, 109, 111) (Fig. 8). 
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FIG. 18. Systemic chimerism by peR of multiple autopsy tissues of patient 77 , 18.4 yr after liver transplantation; death was caused by HBV. 
DN A was extracted from liver (L ), lymph node (LN), lung (LU), thymus (TH), pancreas (P), heart (H), kidney (K ) and intestine (l) and was peR 
amplified with DR4 (donor)-specific primers. A Southern blot of the amplified DNA was hybridized with a DR4 allele-specific oligonucleotide 
probe. In the case of liver, only 1/50 of the amplification product was used. C is the negative control of the peR amplification performed in the 
absence of DNA. 
FIG. 19. Lung and heart graft acceptance is also by the mechanism 
of cell migration and repopulation (see text). Stars represent chimeric 
donor cells. 
The credibility of this explanation is enhanced by 
much earlier analogous observations in experimental 
bone marrow transplant models. The absence of GVHD 
in mixed allogeneic chimeras was observed and empha-
sized by Slavin et al. (112) when rat recipients of the 
bone marrow were conditioned with total lymphoid 
irradiation (TLI) -a procedure that leaves much of the 
host-immune system intact. GVHD resistance was 
demonstrated even more clearly by Ildstad and Sachs 
(113), who concocted various mixtures of donor and 
recipient bone marrow cells ex vivo and then systemat-
ically created mixed allogeneic chimeras by reconsti-
tuting cytoablated recipients with the mixtures. In both 
models the mixed chimeras were able to accept tissue or 
organ grafts from the marrow donor. 
Host Vs. Graft Reactivity (Rejection) and 
Histocompatibility 
It is unknown how the coexisting immunocyte popu-
lations in mixed chimerism come to view each other in 
a revised light. However, it is clear that the resulting 
nonreactivity accounting for GVHD resistance works 
FIG. 20. Fluorescent in situ hybridization for Y chromosome in a 
colon biopsy specimen of a woman who was given a lung allograft from 
a male donor (original magnification x 1,000). peR analysis of the 
same specimen was also positive for male DNA. 
the other way around, with the eventual amelioration of 
whole-organ rejection (host vs. graft rejection, HVG). 
This amelioration occurs relatively slowly under the 
immunosuppressive regimens in current use, even in the 
most successful cases. The extent and stability of the 
nonreactivity months or years later may not require 
continued immunosuppression in some recipients of the 
immunologically "easier" liver graft (see later) and even 
occasionally with the less-favorable circumstances of 
kidney transplantation (14, 114). 
In both directions (GVH and HVG), cellular interac-
tions that result in "mutual natural immunosuppres-
sion" are envisioned as occurring on a sliding scale in 
which each further level of histoincompatibility pro-
vokes countervailing, although not equal, increases in 
initial response (Fig. 27) . If the short-term storm can be 
weathered long enough to allow mutual cell "accommo-
dation," as has been more and more possible under the 
protective umbrella of modern day immunosuppression, 
the anticipated typing effect dwindles. Such reciprocal 
clonal expansion followed by peripheral clonal inacti-
vation has been called exhaustive clonal differentiation 
by Webb, Morris and Sprent (115) . Both at the outset 
and in the aftermath, the number of peripheralized 
donor cells is small compared with the recipient leu-
kocyte population. Figure 28 depicts a kidney with a 
relatively small leukocyte army of which remnants 
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FIG. 21. Sites of action of immunosuppressive drugs. All can induce 
a state of donor-specific nonreactivity if they permit cell migration and 
repopulation. 
remained identifiable in recipient tissues for the lifetime 
of the graft (Table 2) . 
With this frame of reference, it is understandable why 
transplant surgeons have continued to report that HLA 
matching of the donor and recipient does not accurately 
predict the outcome of cadaver kidney transplantation 
(116-119) or of transplantation of extrarenal organs 
including the liver (120, 121), whereas it is universally 
accepted that a perfect or near-perfect match is a 
supreme determinant of success for bone marrow 
transplantation under conditions of recipient cyto-
ablation (104, 105, 122). 
Failure of Mixed Chimerism 
Failure of the chimeric and recipient immunocytes to 
reach an immunological "truce" leads to rejection of the 
transplanted whole organ on one hand, to GVHD on the 
other or sometimes to both simultaneously. This finding 
has been partiCUlarly well studied after intestinal trans-
plantation between certain rat strain combinations such 
as Lewis (LEW) and Brown Norway (BN) (12,46,47). In 
LEW rats treated daily with variable doses ofFK 506 for 
14 days and weekly thereafter, successful intestinal 
transplantation from fully allogeneic BN donors was not 
complicated by either rejection or by fatal GVHD (12). In 
contrast, with LEW to BN, rejection was difficult to 
control, and GVHD invariably developed when daily 
treatment was stopped (46, 47). Yet, the two-way 
lymphocyte traffic from graft-to-host lymphoid organs 
and vice versa was similar with either strain direction. 
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Saat et al . (123) have described analogous findings of 
GVHD predisposition and rejection under cyclosporine 
after WAG to BN rat intestinal transplantation but not 
BN to WAG. 
Further experiments in our laboratory have not 
clarified why the BN rat is an "easy" donor and 
"difficult" recipient (47). At a clinical level, the unre-
solved practical question is how to identify and avoid bad 
donor-recipient combinations analogous to LEW to BN, 
particularly when immunologically active organs such as 
the intestine and liver are engrafted. 
With human liver transplantation, preoccupation 
with rejection obscured the fact until recently that the 
GVH reaction, which is an incipient process and a 
requisite for sustained engraftment in every case, can 
evolve to serious or fatal syndromes (124-130) in the 
early postoperative period. Clinically significant GVHD 
is observed in our liver program in approximately 5% of 
cases, manifesting as dermatitis. In the past, this usually 
was attributed to a self-limiting drug reaction or an 
allergic manifestation (Starzl et aI., Unpublished obser-
vations, 1993). 
Although most of these patients can be treated 
successfully with increased immunosuppression (partic-
ularly prednisone), those with extensive skin in-
volvement, gastrointestinal symptoms and depression of 
the formed blood elements have a high mortality (129). 
The chimerism that has been documented in such 
patients has differed quantitatively from that seen in 
those after a benign convalescence. Some illustrative 
cases follow. 
Case 1: GVHD with Lymphoproliferative Disease. On 
October 10, 1991, a 37-yr-old man with a neuroendo-
crine malignancy underwent exenteration of the native 
liver, pancreas, spleen, duodenum and part of the 
stomach, followed by liver transplantation . Control of 
rejection required excessive immunosuppression during 
the first 3 wk, including a course of OKT3. GVHD was 
suspected because of a skin rash after 3V2 wk and was 
confirmed with a skin biopsy on the 34th day. Despite 
increases or decreases of immunosuppression, the pa-
tient deteriorated inexorably with sepsis, cardiovascular 
instability and multiple organ failure until his death on 
the 53rd day. At autopsy, donor cells were found in all 
recipient tissues. In addition, a widespread Epstein-Barr 
virus-positive polyclonal posttransplant lymphoprolif-
erative disorder involving predominantly the liver and 
lymph nodes was found . The hepatic graft had an 
atypical portal and lobular infiltrate composed of a 
mixture of donor and recipient cells (60 : 40), of which 
most were B lymphocytes. 
Case 2: GVHD Reversal with Immunosuppres-
sion. On June 4, 1992, a 34-yr-old woman with a 
neuroendocrine tumor had a procedure similar to that in 
case 1, plus pancreatic islet infusion from the same 
donor into the hepatic graft portal vein. She was 
discharged after 41/2 wk but was readmitted on July 29, 
1992, with bacteremia and a skin rash that on biopsy 
contained evidence of chimerism and GVHD including 
apoptosis (Fig. 29). The rash and other findings were 
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FIG. 22. The mutual leukocyte engagement and interaction after whole-organ transplantation of cell migration. This is in essence a two-way 
in vivo MLR. 
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FIG. 23. Absence of the two-way cell interaction with the removal (cytoablation) or nonreactivity (Billingham-Brent-Medawar and F 1 hybrid 
models) of one population. These conditions are the in vivo equivalents of the one-way MLR shown in Figure 24. They are conducive to the 
development of GVHD. Stars represent chimeric donor cells. 
controlled with increased immunosuppression including 
1 gm prednisolone, and she was discharged 11 days later 
with good graft function. 
Case 3: GVHD Reversal with Stored Autologous Bone 
Marrow. A 56-yr-old man with gastric leiomyosarcoma 
and liver metastases underwent liver transplantation on 
July 16, 1992, after an upper-abdominal exenteration 
similar to that in cases 1 and 2 but differing by the 
addition of a radical lymph node dissection and 
by preservation of the proximal pancreas and 
duodenum. 
Just before surgery, the patient was prepared with a 
single dose of 5.5 Gy thoracoabdominal lymphoid irra-
diation followed by an intravenous dose of 19 x 109 
non purged bone marrow cells. During the first postop-
erative week, he developed a skin rash in areas exposed 
to the irradiation. Although mild initially, this rash 
spread steadily to more than 80% of the body including 
the face, palms and soles with alarming desquamation 
and excoriation and with transient bouts of eosinophilia 
(2,040 mm3 ) and diarrhea. 
The diagnosis of GVHD was made in a skin biopsy 
specimen on the 34th postoperative day (Fig. 30). The 
rash was unresponsive to either increases or decreases of 
immunosuppression. On August 27 and the following 
morning (the 42nd and 43rd postoperative days, respec-
tively) 1.23 x 108 and 1.6 x 108 unpurged bone marrow 
cells per kilogram (collected and stored from before the 
preoperative TLl) were infused intravenously. The skin 
rash dramatically resolved over the next 2 wk coincident 
with a fall in mixed lineage donor cells in the blood from 
approximately 25% of total to 3% by flow cytometry. 
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FIG. 24. One-way MLR in which only one cell population is reactive. This is the in vitro analog of the in vivo models shown in Figure 
23. 
Solid Organ Bone Marrow 
Uncommon £II 
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FIG. 25. The division of transplantation into two separate disciplines by divergent therapeutic dogmas that created one-way vs. two-way in 
vivo MLR analogs. The policies used in bone marrow transplantation inhibited or precluded bidirectional cell migration, whereas this 
phenomenon was the fundamental basis for graft acceptance with the policies of whole-organ transplanters. 
Liver function remained normal, and the patient was 
discharged 2 wk later. 
On October 13 he was readmitted with jaundice. 
Findings on a needle biopsy ofthe liver were interpreted 
as acute HCV. Because of an additional suspected partial 
biliary obstruction, the choledochojejunostomy was re-
vised on October 22, 1992, and at reoperation another 
liver biopsy sample was obtained in which the histo-
pathological diagnosis of HCV was confirmed with PCR 
demonstration of the viral DNA. Sparse donor cells still 
were present in a recipient lymph node and in a segment 
of bowel excised for the biliary reconstruction (Fig. 30). 
After the biliary tract operation, minimum immuno-
suppression was given (FK 506 1 mg every other day and 
prednisone 5 mg/day). Interferon alfa therapy was 
started on October 27. The bilirubin level reached a peak 
of 21.9 mg/dl on October 30 but slowly declined to 2.8 
mg/dl by the time the patient was discharged on 
November 20. 
Case 4: GVHD, LPD and Recurrent HCC. On April 1, 
1989, a 56-yr-old woman with micronodular cirrhosis 
underwent orthotopic liver transplantation from a male 
donor. A skin rash 5 wk later (May 6) was diagnosed 
initially as a drug reaction. Nine weeks after transplan-
tation, she underwent an excisional biopsy of a cervical 
lymph node that showed diffuse plasmacytoid and 
lymphoblastic infiltration. The diagnosis was posttrans-
plantation LPD that had both female and male cells (Fig. 
31). This was treated successfully with a reduction of 
immunosuppression and a course of acyclovir. 
Two years later in June 1991, she was found to have 
an unresectable multicentric HCC in her liver allograft. 
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FIG. 26. Explanation for uncontrollability of GVHD with major 
histocompatibility complex-mismatched donors when mutual cell 
engagement is prevented, thereby eliminating the element of mutual 
natural immunosuppression that is shown in Figure 27 . 
The tumor did not contain cells with the Y chromosome, 
prompting reexamination of her cirrhotic native liver. 
The diagnosis was made of metastases from a previously 
undiagnosed HCC of the native liver, and she began 
chemotherapy in August 1991. The mass lesions in the 
liver have continued to grow, and she has developed 
pulmonary metastases. 
Comments. In all four cases a potential donor-
recipient immunological imbalance preexisted or was 
produced by the conditions of treatment. Although it 
was not measured, the loss of recipient immunological 
surveillance that has been associated with malignant 
tumors or with prior chemotherapy may have occurred. 
In addition, three ofthe four patients had lymphoid-rich 
upper-abdominal viscera resected, including the 
spleen. 
In case 3, the recipient also underwent TLI and a 
donor bone marrow infusion. Florid multilineage blood 
chimerism in this patient developed during the first 
month, coincident with clinical GVHD. The response of 
the patient to treatment with autologous bone marrow 
was dramatic. The ability of the stored autologous 
marrow cells to turn off the potentially lethal GVHD 
may be a clue to the changes that occur during the 
mutual cell engagement of mixed chimerism. Although 
the cells used for rescue from GVHD were thought to be 
smaller in number than those in the circulation of the 
patient, they had not been exposed to donor marrow. 
Their therapeutic effect resembled the ability of virgin 
donor strain immunocytes to "break tolerance" as 
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FIG. 27. The reciprocal alteration of alloreactivity by coexisting 
immunocyte populations (mixed allogeneic chimerism). The cardinal 
requirement for GVHD resistance is to preserve both populations 
contributing to the reaction. The factor of mutual natural immuno-
suppression also explains the nondiscrimination of HLA matching in 
predicting the outcome after whole-organ transplantation (see text). 
originally described by Billingham, Brent and Medawar 
(131). 
Hepatic Tolerogenicity and Its Implications 
That every long-surviving organ recipient in this 
study, whether under immunosuppression or not, was 
found to have chimerism is in accord with our hypothesis 
that cell migration and repopulation is the central 
mechanism of acceptance of all whole-organ grafts (5, 6). 
Although this is a generic process, quantitative differ-
ences exist between organs that we attribute to the 
variable density of the potentially migratory dendritic 
cells, macrophages and lymphoid collections. The heavy 
endowment of the liver with macrophages, Kupffer cells 
and dendritic cells is a particularly striking feature that 
invites further speculation about the role of these cells 
in the well-known tolerogenicity of this organ. 
The immunological advantage of the liver relative to 
other organs includes a greater ease of inducing the 
acceptance of hepatic allografts or xenografts after 
a limited course of immunosuppression (4, 25, 132) or 
in swine (133-135) and some rat strain combinations 
(136, 137) with no treatment at all. In addition, the 
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FIG. 28. The David (kidney) and Goliath (recipient) conditions of kidney transplantation in which the graft brings a limited number of 
leukocytes to the mutual cell engagement. Nevertheless, the migratory donor leukocytes were demonstrated in all of the patients with 
continuously surviving allografts who underwent biopsies 27 to 29 yr after transplantation . Stars represent chimeric donor cells. 
FIG. 29. Skin biopsy specimen of a female recipient of a liver and pancreatic islets obtained from a male donor. The clinical and 
histopathological diagnosis was GVHD. This was easily controlled with increased immunosuppression. (A) The skin was stained for donor (Bw4) 
antigen , showing infiltrating cells of donor specificity. These cells also stained positive for the Y probe (not shown). (B) Stain for recipient (A3) 
antigen in same specimen, showing normal distribution of recipient cells (original magnification x 200). 
transplanted liver graft is relatively resistant to the 
preformed antigraft antibodies that cause hyperacute 
rejection of the kidney and heart (138-141). Another 
quality is its unusual ability to induce a state of 
unresponsiveness to other tissues and organs trans-
planted concomitantly or subsequently from the donor 
or donor strain (136, 139, 142) and even to shield these 
organs from the hyperacute rejection caused by pre-
formed aIlospecific (143) or xenospecific (144) donor 
antibodies. In all of these circumstances, the liver can 
quickly transform the recipient environment to one 
more favorable for all donor tissues including itself. 
These foregoing observations have been attributed to 
"hepatic tolerogenicity," incorrectly we believe because 
the term implies that the hepatocytes are responsible. 
We propose that the crucial variable distinguishing the 
tolerogenicity of one organ graft from another under 
effective immunosuppression is its leukocyte (not its 
parenchymal) component, in a reversal of the immuno-
genic role described classically for these cells (77-82, 
84-91). Thus, because of its dense constituency of these 
migratory leukocytes, the liver is high on the favorable 
tolerogenic list with the lung and intestine following and 
the kidney and heart bringing up the rear (Fig. 32). 
Experimental studies showing less-striking toleroge-
nicity of the lymphoreticular-rich spleen (145-147), 
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FIG. 30. Infiltrative donor cells in the (A) epidermis and (B) adnexa in a patient with clinical GVHD 34 days after combined liver and bone 
marrow transplantation (antibodies to B55; original magnification x 200). (e) The GVHD was progressive and at 6 wk stored, autologous 
(recipient) bone marrow was infused. At 14 wk this wedge biopsy specimen of the liver showed that the biliary epithelium and endothelium were 
of donor origin (antibodies to B55; original magnification x 250). (D) Biliary epitheliulU and endothelium were negative for recipient antigens. 
A few positive infiltrative recipient cells were noted (antibodies to A2; original magnification x 250). (E) Scattered donor cells were detected in 
the lamina propria of a small bowel biopsy sample, indicating that microchimerism persisted after the GVHD was eliminated (antibodies to Bw4; 
original magnification x 400). 
intestine (1 2) and lung (74,75) are compatible with this 
generalization. 
Strategies to elevate the underprivileged kidney and 
heart to the same level of advantage as the liver could be 
by the perioperative infusion of lymphoreticular cells 
obtained from bone marrow of the organ donor or 
possibly from the spleen. The strategy of concomitant 
infusion of bone marrow from the whole-organ donor 
proposed by Ildstad et al. (148) also has been advocated 
by Monaco et al. (149, 150) and Thomas et al. (151) for 
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FIG. 31. Studies in a female recipient of a male donor's liver, who 
developed GVHD and a B-cell lymphoma in the first 3 postoperative 
mo . Note the Y chromosomes in a cervical lymph node biopsy sample 
containing an Epstein-Barr virus-positive posttransplant lymphopro-
liferative disorder (fluorescent in situ hybridization for Y chromosome; 
original magnification x 400). Double labeling for the Y probe and 
lymphocyte phenotypic markers revealed that at least one third of the 
donor cells were activated T cells (UCHL-1 +, not shown). 
FIG. 32. The explanation for the variable ability under immuno-
suppression to induce acceptance and ultimately tolerance of different 
organs. We postulate that the dendritic leukocyte is the single most 
important, although not the only, tolerogenic cell. The tissue content 
of these potentially migratory cells is liver > intestine> 
lung> kidney and heart. Stars represent chimeric donor cells in the 
recipient. 
tolerance induction of kidneys and carried out clinically 
by Barber et al. (152). Now, the cycle is complete because 
this was the starting point of acquired allograft tol-
erance for Billingham, Brent and Medawar (99) and then 
Main and Prehn (100) . 
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FIG. 33. Hamster cells in the interstitium of the recipient heart 100 
days after hamster-to-rat xenotransplantation (hamster antibody 
immunofluorescence; original magnification x 400). The periarterial 
lymphatic sheath of the spleen also contained these cells. 
LI HE LU KI L LN HU 
1 2 
FIG. 34. PCR amplification of a baboon-specific DNA from recipient 
tissues. Lane L1 is the PCR product from the baboon liver and contains 
only 1% of the PCR reaction so that the other lanes won 't be 
overwhelmed (HE, heart; LU, lung; Kl, kidney; LNI and LN2, lymph 
nodes 1 and 2; and HU, human blood used as a negative control). 
WHOLE-ORGAN XENOTRANSPLANTATION 
When organs are transplanted from a significantly 
disparate species, the first immunological hurdle is that 
of preformed xenospecific antibodies, which quickly 
devascularize the graft and exclude it from recipient 
circulation by damaging its blood vessels (153). If this 
barrier can be surmounted, the process of xenograft 
acceptance involves the same bidirectional cell migration 
and consequent systemic chimerism as with allotrans-
plantation. After hamster-to-rat xenotransplantation, 
the cells displaced from the xenografts can be detected in 
widespread rat recipient tissues with polyclonal rat-
absorbed hamster leukocyte antibodies (Fig. 33) and 
confirmed with peR techniques (154, 155). As with 
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allotransplantation, the chimerism is more extensive 
after liver than after heart transplantation . 
, Chimerism was observed recently in a patient who 
survived for 70 days after receipt of a baboon liver (Fig. 
34). Death was caused by infectious complications and 
by complications of biliary stasis rather than rejection or 
GVHD (156). This means that successful clinical xe-
notransplantation must be visualized along the same 
lines of donor-recipient cellular migration and repopu-
lation, as with allograft acceptance. 
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